A multi-centre study of efficacy and safety of Intratect®, a novel intravenous immunoglobulin preparation

Clinical and Experimental Immunology

Volumn 161, Issue 3, 2010, Pages 512-517

  Kreuz, W ^a   Erdos M ^b   Rossi, P ^c   Bernatowska, E ^d   Espanol, T ^e   Marodi L ^b  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^d CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Intravenous immunoglobulin; Primary immunodeficiency

Indexed keywords

IMMUNOGLOBULIN; INTRATECT; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; BRONCHITIS; CHILD; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; COUGHING; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; FEMALE; FEVER; HUMAN; IMMUNE DEFICIENCY; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; OBSERVATIONAL STUDY; PHARYNGITIS; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; RHINITIS; SINUSITIS; TRACHEITIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AREA UNDER CURVE; BRONCHITIS; CHILD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOLOGIC FACTORS; INFECTION; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PROSPECTIVE STUDIES; SINUSITIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77955751034     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2010.04187.x     Document Type: Article

References (18)

1. Buckley RH, Schiff RI. The use of intravenous immune globulin in immunodeficiency diseases. N Engl J Med 1991 325 : 110 117.
2. Chapel H. Consensus on diagnosis/management of primary antibody deficiencies. Br Med J 1994 308 : 581 585.
3. Orange JS, Hossny EM, Weiler CR et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006 117 : S525 53.
4. Primary immunodeficiency diseases: report of a WHO sponsored meeting. Immunodefic Rev 1989 1 : 173 205.
5. NIH Consensus Conference. Intravenous immunoglobulin. Prevention and treatment of the disease. JAMA 1990 264 : 3189 3193.
6. Jolles S, Sewell WA, Misbah SA. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol 2005 142 : 1 11.
7. Sibéril S, Elluru S, Negi VS et al. Intravenous immunoglobulin in autoimmune and inflammatory diseases: more than mere transfer of antibodies. Transfus Apher Sci 2007 37 : 103 107.
8. Schiff RI, Williams LW, Nelson RP, Buckley RH, Burks W, Good RA. Multi-centre crossover comparison of safety and efficacy of Intraglobin-F with Gamimune-N, Sandoglobulin, and Gammagard in patients with primary immunodeficiency diseases. J Clin Immunol 1997 17 : 21 8.
9. The European Evaluation Agency for Medicinal Products: Note for Guidance on the Clinical Investigation of human Normal Immunoglobulin for Intravenous Administration (IVIG). CPMP/BPWG/388/95; Rev. 1, 2000.
10. Guidance for Industry: safety, efficacy, and pharmacokinetic studies to support marketing of intravenous immune globulin as replacement therapy for primary humoral immunodeficiency. USA FDA Deptartment of Health and Human Services. Draft, November 2005.
11. Roifman CM, Schroeder H, Berger M et al. Comparison of efficacy of IVIG-C, 10% (caprylate/chromatography) and IVIG-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial. Int Immunopharmacol 2003 3 : 1325 1333.
12. Ochs HD, Pinciaro PJ, the Octagam Study Group. Octagam® 5%, an intravenous IgG product, is efficacious and well-tolerated in subjects with primary immunodeficiency diseases. J Clin Immunol 2004 24 : 309 314.
13. Berger M, Pinciaro PJ, the Flebogamma® 5% investigators. Safety, efficacy, and pharmacokinetics of Flebo-gamma® 5% for replacement therapy in primary immunodeficiency diseases. J Clin Immunol 2004 24 : 389 396.
14. Nolte MT, Pirofsky B, Gerritz GA, Golding B. Intravenous immunoglobulin therapy for antibody deficiency. Clin Exp Immunol 1979 36 : 237 243.
15. Church JA, Leibl H, Stein MR et al. Efficacy, safety, and tolerability of a new 10% liquid intravenous immunoglobulin [IGIV 10%] in patients with PID. J Clin Immunol 2006 26 : 388 395. (Pubitemid 44051386)
16. The European Evaluation Agency for Medicinal Products: Core SPC for Human Normal Immunoglobulin for Intravenous Administration (IVIG). CPMP/BPWG/859/95; Rev. 2, 2000.
17. Webster AD. Clinical and immunological spectrum of common variable immunodeficiency. Iran J Allergy Asthma Immunol 2004 3 : 103 113.
18. Knezevic-Maramica I, Kruskall MS. Intravenous immunoglobulins: an update for clinicians. Transfusion 2003 43 : 1460 1480.